Plaintiff OFA Appeals Foley & Lardner LLP, accessed December 19, 2025, Navigating the Safe Harbor: Guidance from the Courts on Qualifying for the 35 USC 271(E)(1) Exemption From Patent In, accessed December 19, 2025, Safe Harbor for Preclinical Use of Patented Inventions in Drug Research and Development: Merck KGaA v
10.1177/13872877241313031 145 TolleyK.OliverN.MirandaE.Migliaccio-WalleK.BozkayaD.LiQ
Case reports include isolated cardiac events after stimulant supplement use - see a published case report of STEMI after supplement use for an example
I urge you to read my post on the long-term dangers and side effects of GLP-1 peptide drugs
Monitoring is still warranted
But with those results come some aesthetic challenges: This has given rise to popular terms like "Ozempic face," which refers to the gaunt or hollow appearance some clients experience